Clinical analysis of acute heart failure's risk factor for chronic myelogenous leukemia patient during the early stage of allogeneic hematopoietic stem cell transplantation.
- Author:
Ke-Feng SHEN
1
;
Qian-Li JIANG
2
;
Qi-Fa LIU
3
;
Jing SUN
1
;
Huai-Ming WANG
1
;
Dan XU
1
;
Yu ZHANG
1
;
Zhi-Ping FAN
1
;
Fen HUANG
1
;
Hong-Sheng ZHOU
1
;
Xiao-Fang LI
1
;
Yong-Qiang WEI
1
;
Min DAI
1
;
Fan-Yi MENG
1
;
Mo YANG
1
Author Information
- Publication Type:Journal Article
- MeSH: Acute Disease; Allografts; Antilymphocyte Serum; Benzamides; Heart Failure; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Imatinib Mesylate; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Retrospective Studies; Risk Factors
- From: Journal of Experimental Hematology 2015;23(1):178-182
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVEThe study was to analyze the acute heart failure's risk factors and clinical characteristics for the patient with chronic myelogenous leukemia (CML) during the early stage (within 100 d) of allogeneic hematopoietic stem cell transplantation (allo-HSCT).
METHODSA total of 106 cases of CML received allo-HSCT were retrospectively studied in Nanfang Hospital from May 2003 to May 2013. On the basis of existence or absence of acute heart failure during early stage of allo-HSCT (100 d), the patients were divided into heart failure (15 cases) and control group (91 cases). Using Logistic univariate analysis, Fisher' exact test and Pearson X(2) test, the acute heart failure's risk factors and clinical characteristics of both groups were analyzed.
RESULTSThe median occurrence time of acute heart failure was 3 d (1 d before transplantation to 84 d after transplantation). Logistic univariate analysis indicated that the imatinib treatment history and time, and the prophylaxis regimens for GVHD with anti-thymocyte globulin (ATG) were all the poor prognostic factors for acute heart failure. Incidence of hepatic veno-occlusive disease (HVOD), bacterial infection and adverse prognostic events including death in the heart failure group patients were statistically higher than that in control group (P < 0.05).
CONCLUSIONAcute heart failure mostly happened in the early stage after allo-HSCT, imatinib treatment and GVHD prophylaxis regimens with ATG are the poor prognostic factors for acute heart failure. The patients of heart failure group seem to have higher incidence of hepatic veno-occlusive disease (HVOD), bacterial infection and deaths.
